UroGen files sale of 10,000 shares

UroGen Pharma Ltd. reported a Form 144 notice showing the sale of 10,000 shares of common stock.

Rhea-AI Filing Summary

UroGen Pharma Ltd. reported a Form 144 notice showing the sale of 10,000 shares of common stock. The filing lists the sale date as 05/08/2026 with aggregate proceeds of $300,048.00. The underlying shares were issued on 01/27/2023 following a stock option exercise.

Insights

Securities Compliance Analyst

Form 144 sale notice for 10,000 shares with $300,048 proceeds.

The filing lists a 10,000-share sale reported on 05/08/2026, showing aggregate proceeds of $300,048.00. The shares trace to a stock option exercise dated 01/27/2023.

Regulatory treatment appears routine: the notice documents a broker-assisted resale on NASDAQ through RBC Capital Markets. Timing, selling holder identity, and whether sales were part of a larger plan are not detailed in the excerpt.

Key Figures

Shares sold: 10,000 shares Aggregate proceeds: $300,048.00 Origin of shares: Stock option exercise

3 metrics

Shares sold 10,000 shares sale date <date>05/08/2026</date>

Aggregate proceeds $300,048.00 proceeds reported in Form 144

Origin of shares Stock option exercise exercise date <date>01/27/2023</date>

Key Terms

Form 144, Stock option exercise, Aggregate proceeds

3 terms

Form 144 regulatory

"Form 144 notice showing the sale of 10,000 shares"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Stock option exercise financial

"STOCK OPTION EXERCISE | ISSUER | 01/27/2023"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Aggregate proceeds financial

"10000 | 300048.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does UroGen's (URGN) Form 144 report show?

The Form 144 reports a sale of 10,000 shares of common stock for $300,048.00, with the sale date listed as 05/08/2026. The shares originated from a stock option exercise dated 01/27/2023.

Who acted as broker for the sale reported in the Form 144?

RBC Capital Markets LLC is named as the broker-dealer in the filing, with an address in Minneapolis. The filing indicates the transaction was executed on NASDAQ and routed through that brokerage firm.

Does the Form 144 specify who the selling holder is?

The filing identifies a contact name, Mark Schoenberg, associated with RBC Capital Markets. The excerpt does not provide a broader selling-stockholder table or additional beneficial-ownership details for the holder.

Are the proceeds and origin of the shares disclosed?

Yes. The excerpt shows aggregate proceeds of $300,048.00 for 10,000 shares, and indicates the shares were issued following a stock option exercise on 01/27/2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 03:53 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001763581
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	UroGen Pharma Ltd.
SEC File Number	001-38079
Address of Issuer	9 HA'TA'ASIYA ST RA'ANANA ISRAEL 4365007
Phone	972 9 770 7601
Name of Person for Whose Account the Securities are To Be Sold	Schoenberg Mark
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	RBC CAPITAL MARKETS LLC 250 NICOLLET MALL, SUITE 1700 MINNEAPOLIS MN 55401	10000	350143.00	48721701	06/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/27/2023	STOCK OPTION EXERCISE	ISSUER			10000	01/27/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MARK SCHOENBERG C/O RBC CAPITAL MARKETS LLC 250 NICOLLET MALL MINNEAPOLIS MN 55401	UROGEN PHARMA LTD	05/08/2026	10000	300048.00

144: Remarks and Signature

Remarks	SOLD PURSUANT TO A RULE 10B5-1 PLAN ESTABLISHED 8-20-25
Date of Notice	06/22/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/20/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	POA / JEFFREY EISCHENS
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)